Dose Dense MVAC for Muscle Invasive Bladder Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01031420
Recruitment Status : Completed
First Posted : December 14, 2009
Last Update Posted : November 4, 2015
Information provided by (Responsible Party):
Fox Chase Cancer Center

December 3, 2009
December 14, 2009
November 4, 2015
December 2009
July 2013   (Final data collection date for primary outcome measure)
To assess the rate of complete response at cystectomy or ureterectomy following preoperative dose dense MVAC in patients with muscle invasive urothelial carcinoma of the bladder or high risk upper tract urothelial carcinoma. [ Time Frame: Following completion of the 3rd/final cycle of chemotherapy (about week 9) by CT imaging and at time of surgery for pathologic response. ]
Same as current
Complete list of historical versions of study NCT01031420 on Archive Site
To assess the toxicity profile of dose dense MVAC given in the neoadjuvant setting. [ Time Frame: Ongoing throughout treatment at each MD visit every 14 days. ]
Same as current
Not Provided
Not Provided
Dose Dense MVAC for Muscle Invasive Bladder Cancer
Phase II Trial of Neoadjuvant Dose Dense MVAC in Muscle Invasive Bladder Cancer and High Risk Urothelial Carcinoma of the Upper Urinary Tract
Standard treatment for early stage bladder cancer is chemotherapy with methotrexate (M), vinblastine (V), adriamycin (A), and cisplatin (C) followed by surgical removal of any remaining cancer and the bladder with the intent of cure. The MV chemotherapy is usually given every 14 days with the AC given along each 28 days. This study looks at giving the same drugs at the same doses closer together, all drugs every 14 days, with the support of growth factor medication to promote growth of the white blood cells and platelets and allow chemotherapy to be finished sooner and surgery to be done sooner.

Primary Objective To assess the rate of complete response (pT0) at cystectomy or ureterectomy following preoperative dose dense MVAC (DD-MVAC) in patients with muscle invasive urothelial carcinoma of the bladder or high grade upper tract urothelial carcinoma.

Secondary Objectives To assess the toxicity profile of DD-MVAC when given in the neoadjuvant setting: To define the number of patients who complete all three cycles of treatment without dose reduction, and to compare incidence of toxicity to the historical standard described by Grossman et al. To assess the 5 year overall and relapse free survival in patients who receive neoadjuvant DD-MVAC. To compare complete response rates between the following subgroups of study patients: Among bladder patients: Clinical N0 versus N1 (Appendix B) Among bladder patients: T2 stage without high risk features versus T2 with high risk features plus those with > T2 stage.

Three 14 day cycles of:

Methotrexate 30 mg/m2 IV push or infusion over 2-3 minutes. Day 1

Vinblastine 3 mg/m2 Slow IV push or infusion over Day 1

Doxorubicin 30 mg/m2 Slow IV push or infusion over 15 minutes Day 1

Cisplatin 70 mg/m2 IV infusion over 4 hours Note: May divide dose over two sequential days (35 mg/m2/d x 2 days) if creatinine clearance 50-59 mL/min Day 1* (or divided over Day 1 and Day 2)

Pegfilgrastim 6 mg SQ 24-48 hours after completion of chemotherapy.

Followed in 4-8 weeks by radical cystectomy/ureterectomy.

Phase 2
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • Muscle Invasive Bladder Cancer
  • High Risk Urothelial Carcinoma of the Upper Urinary Tracts
Drug: single arm dose dense MVAC
standard doses of methotrexate, vinblastine, adriamycin, and cisplatin given every 14 days.
Other Names:
  • methotrexate sodium
  • MTX
  • Mexate
  • Mexate-AQ
  • Foex
  • Folex
  • Abitrexate
  • Rheumatrex
  • amethopterin
  • Velban
  • Velsar
  • AlkabanAQ
  • Velbe
  • vinblastine sulfate
  • vincaleukoblastine
  • VLB
  • doxorubicin
  • doxorubicin hydrochloride liposomal Doxil,
  • Rubex
  • Adria
  • cis-platinum, cisdiammineddichloroplatinum,
  • CDDP
  • Platinol
  • platinum
Experimental: dose dense MVAC
standard doses of MVAC given every 14 days x 3.
Intervention: Drug: single arm dose dense MVAC
Plimack ER, Hoffman-Censits JH, Viterbo R, Trabulsi EJ, Ross EA, Greenberg RE, Chen DY, Lallas CD, Wong YN, Lin J, Kutikov A, Dotan E, Brennan TA, Palma N, Dulaimi E, Mehrazin R, Boorjian SA, Kelly WK, Uzzo RG, Hudes GR. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity. J Clin Oncol. 2014 Jun 20;32(18):1895-901. doi: 10.1200/JCO.2013.53.2465. Epub 2014 May 12.

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
July 2013
July 2013   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • histologically confirmed urothelial carcinoma of bladder, ureter, or renal pelvis. T2-T4 and muscle invasion must be established by TURBT. Upper tract must be high grade. N0-N1 are eligible.
  • candidate for radical cystectomy, nephroureterectomy, or segmental ureterectomy with goal of cure.

    ->/= 18 years old

  • ECOG performance status 0-1.
  • Adequate marrow and organ function.
  • May enter on therapeutic anticoagulation if it can be safely held during perioperative period.
  • No women of childbearing potential, pregnant or breastfeeding.
  • LVEF >/= 50 %
  • Patients with history of other non-urothelial malignancies may enroll if: 1)no evidence of distant disease w/in last year. 2)No anticancer treatment for >/= 1 year other than adjuvant treatment or treatment for secondary prevention. 3) Less than 360 mg/m2 lifetime dose of adriamycin.
  • ability to understand and willingness to sign written informed consent and HIPAA.

Exclusion Criteria:

  • Intravesicular therapy w/in 4 weeks of study entry or those who have not recovered from adverse effects of such agents administered more than 4 weeks earlier.
  • Patients may not be receiving any investigational agents within 4 weeks of study entry.
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to Methotrexate, Vinblastine, Adriamycin or Cisplatin or other agents used in the study.
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Pregnant women are excluded from this study due to the potential for teratogenic or abortifacient effects of cytotoxic chemotherapy.
  • Known HIV-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with cytotoxic chemotherapy. In addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy.

    -. Patients who have undergone prior pelvic radiation are excluded due to risk of life threatening myelosuppression.

  • Patients who have received any previous systemic chemotherapy or radiation therapy for urothelial carcinoma or cytotoxic chemotherapy for another malignancy within 1 year of study entry are ineligible.
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States
NCI-2010-01910 ( Registry Identifier: NCI Clinical Trials Reporting Office )
Not Provided
Not Provided
Fox Chase Cancer Center
Fox Chase Cancer Center
Not Provided
Principal Investigator: Elizabeth Plimack, MD Fox Chase Cancer Center
Fox Chase Cancer Center
November 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP